Osteomyelitis
Conditions
Keywords
hematogenous, bone substitute
Brief summary
This is a retrospective study describing the management of osteomyelitis in a referece center, with success and failures.
Detailed description
Chronic osteomyelitis is a serious osteoarticular infection that most often occurs in the long bones (tibia, femur, humerus), responsible for significant morbidity with the risk of fracture and amputation. It is caused by the presence of bacteria in the bone marrow, sometimes responsible for an intraosseous abscess. Chronic osteomyelitis can have a hematogenous or more often exogenous origin, after trauma or surgery. Despite the progress made in both antibiotics and surgical treatment, the probability of failure of this treatment (infectious recurrence) is of the order of 20%, and has unfortunately remained stable for more than 20 years. An innovative treatment, Cerament-G (BONESUPPORT AB Laboratory, Sweden), a synthetic bone substitute composed of hydroxyapatite, calcium sulphate, and gentamicin (CE marking), fills the dead space which is formed during surgery, prevents this cavity filled with blood from becoming infected, and promotes the regeneration of the bone within this space, limiting the risk of fracture in the medium and long term. It also locally delivers very high doses of gentamicin for several weeks.
Interventions
OTHERpatients having had an osteomyelitis since 2017
description of osteomyelitis and their management
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients who presented with osteomyelitis between 2017 and 2021
Exclusion criteria
* Patients who objected to participating in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| rate of osteomyelitis in BJI | between 2017 and 2021 | proportion of patients having had an osteomyelitis |
| site of osteomyelitis | between 2017 and 2021 | localisation |
| bone defect size | between 2017 and 2021 | dimension of the bone defect size |
| type of osteomyelitis | between 2017 and 2021 | hematogenous or after a trauma or after a surgery |
| rate of bacteria involved in osteomyelitis | between 2017 and 2021 | description of bacteria responsible for osteomyelitis |
| Description of patients | between 2017 and 2021 | comorbidities, age |
| Description of the follow up of the patients | between 2017 and 2021 | duration of the follow up of patients |
| description of patients : medical treatment | between 2017 and 2021 | description and duration of antibiotics |
| Description of patients : surgical treatment | between 2017 and 2021 | description of surgery performed |
| rate of patient treated with CERAMENT | between 2017 and 2021 | proportion of patients having had CERAMENT |
| rate of treatment failure | between 2017 and 2021 | treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin |
Countries
France
Contacts
Primary ContactTristan Ferry, Md,PhD
Backup ContactJohanna Boulant, CRA
Outcome results
None listed